- Hypoxia Inducible Factor-1
- IL-13 receptors
- Hypoxia, Brain
- Calcium Channel Antagonists
- Stereotactic radiosurgery versus surgery for single brain metastasis
- Diphtheria toxin-conjugated monoclonal antibody
- Phase II 131-I
Board Certification and Academic Information
||Neurosurgery - Professor
Oncological Sciences - Adjunct Professor
Radiation Oncology - Adjunct Professor
||American Board of Neurological Surgery (Neurosurg)
Academic Office Locations
|Academic Office Phone Number
||Academic Office Address
||School of Medicine
30 N Medical Dr
Salt Lake City, UT 84132
Dr Randy Jensen is a neurosurgeon with a clinical practice focused on treating patients with brain tumors. He has extensive experience utilizing novel surgical methods to maximize tumor removal and minimize surgical complications. He is an expert on the use of preoperative planning and imaging to remove tumors from eloquent areas of the brain. He routinely performs awake craniotomy with intraoperative cortical mapping to avoid motor or speech injury during removal of tumors near these areas of the brain. He has instituted an intraoperative MRI program, the only one available in the Intermountain West. He also co-directs the Stereotactic Radiosurgery program which utilizes the Brain Lab Novalis Frameless Shaped Beam System for precise delivery of radiation for treatment of benign and malignant brain tumors. He and Dr Dennis Shrieve have treated over 1000 patients using these techniques.
Dr Jensen is Professor of Neurosurgery, Radiation Oncology and Oncological Sciences. He is a member of both the Experimental Therapeutics and the Nuclear Control of Cell Growth and Differentiation programs. He has served at a national level for various Neurosurgical Societies and was recently President of the Rocky Mountain Neurosurgery Society. He is the Associate Program Director for the Neurosurgery Residency program and Clerkship Director for medical students rotating on the Neurosurgery Service.
He is a Cancer Research Investigator at the Huntsman Cancer Institute and has a laboratory focused on animal models of meningioma and radiation necrosis. His laboratory studies brain tumor hypoxia and angiogenesis. He is the author of over 100 papers most on topics of brain tumor biology and patient outcome after brain tumor treatment.
He has been the principal investigator of many brain tumor clinical trials and continues to offer cutting edge treatments for patients with brain tumors.